Workflow
Organogenesis (ORGO)
icon
Search documents
Organogenesis (ORGO) - 2025 Q2 - Earnings Call Transcript
2025-08-07 22:00
Organogenesis (ORGO) Q2 2025 Earnings Call August 07, 2025 05:00 PM ET Speaker0Welcome, ladies and gentlemen, to the Second Quarter twenty twenty five Earnings Conference Call for Organogenesis Holdings, Inc. At this time, all participants have been placed in listen only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward ...
Organogenesis (ORGO) - 2025 Q2 - Quarterly Report
2025-08-07 20:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 98-1329150 (State or Other Jurisdiction of Incorp ...
Organogenesis (ORGO) - 2025 Q2 - Quarterly Results
2025-08-07 20:11
Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., (August 7, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: "I'm ple ...
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
Globenewswire· 2025-08-07 20:05
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compa ...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
Globenewswire· 2025-07-22 20:05
Core Viewpoint - Organogenesis Holdings Inc. will report its second quarter fiscal year 2025 financial results on August 7, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results for the second quarter of fiscal year 2025 will be disclosed after the market closes on August 7, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update [2] Group 2: Company Overview - Organogenesis Holdings Inc. specializes in regenerative medicine, focusing on advanced wound care and surgical and sports medicine markets [3] - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3]
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation
Globenewswire· 2025-07-15 13:00
Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward- looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or ...
Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario
Seeking Alpha· 2025-06-09 21:39
Core Viewpoint - The article does not provide any specific insights or analysis related to a company or industry, focusing instead on the author's qualifications and disclosures [1][2][3]. Group 1 - The author holds multiple degrees in engineering, computer science, business management, and computer applications from various institutions [1]. - The author collaborates with another professional but emphasizes independent analysis and adherence to guidelines [1]. - There is a clear statement of no current stock or derivative positions in any mentioned companies, indicating a lack of conflict of interest [2]. Group 2 - The article includes disclaimers about past performance not guaranteeing future results and clarifies that no investment advice is being provided [3]. - It highlights that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article notes that the analysts may not be licensed or certified, which could impact the credibility of the analysis [3].
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-08 23:10
Company Performance - Organogenesis reported a quarterly loss of $0.13 per share, missing the Zacks Consensus Estimate of $0.04, and compared to a loss of $0.02 per share a year ago, representing an earnings surprise of -425% [1] - The company posted revenues of $86.69 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.06%, and down from $109.98 million year-over-year [2] - Over the last four quarters, Organogenesis has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Organogenesis shares have increased approximately 61.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $143.96 million, and for the current fiscal year, it is $0.16 on revenues of $508.6 million [7] Industry Outlook - The Medical - Drugs industry, to which Organogenesis belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]
Organogenesis (ORGO) - 2025 Q1 - Earnings Call Transcript
2025-05-08 22:02
Organogenesis (ORGO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Gary Gillheeney, Sr - Director, President, CEO & Chair of the BoardDavid Francisco - Chief Financial OfficerAaron Wukmir - Healthcare Equity Research Associate Conference Call Participants Ryan Zimmerman - Managing Director & Medical Technology AnalystRoss Osborn - Director, Lead Research Analyst - MedTech and Diagnostics Operator Welcome, ladies and gentlemen, to the First Quarter twenty twenty five Earnings Conference ...
Organogenesis (ORGO) - 2025 Q1 - Earnings Call Transcript
2025-05-08 22:00
Organogenesis (ORGO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Welcome, ladies and gentlemen, to the First Quarter twenty twenty five Earnings Conference Call for Organogenesis Holdings, Inc. At this time, all participants have been placed in a listen only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward l ...